Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience ABOSTO:ATORX EV-to-OCF is -0.31 as of Sep. 10, 2026. The stock has 6 warning signs investors should review. Among 1,404 Biotechnology companies, Alligator Bioscience AB ranks worse than 70.44% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Alligator Bioscience AB's Enterprise Value is kr35.50 Mil.
Alligator Bioscience AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr-114.15 Mil. Therefore, Alligator Bioscience AB's EV-to-OCF for today is -0.31.
The historical rank and industry rank for Alligator Bioscience AB's EV-to-OCF or its related term are showing as below:
OSTO:ATORX'
s EV-to-OCF Range Over the Past 10 Years
Min: -42.16 Med: -2.04 Max: 0.45
Current: -0.32
During the past 12 years, the highest EV-to-OCF of Alligator Bioscience AB was 0.45. The lowest was -42.16. And the median was -2.04.
OSTO:ATORX's EV-to-OCF is ranked worse than 70.44% of 1404
companies
in the Biotechnology industry
Industry Median: -3.45
vs OSTO:ATORX: -0.32
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alligator Bioscience AB (OSTO:ATORX) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alligator Bioscience AB's PE Ratio (TTM) for today is calculated as:
Alligator Bioscience AB's share price for today is kr0.024.
Alligator Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.601.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ATORX vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's EV-to-OCF falls into.
Alligator Bioscience AB's current Enterprise Value is kr35.50 Mil.
Alligator Bioscience AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-114.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB (OSTO:ATORX) has a EV-to-OCF of -0.31 as of Sep. 10, 2026. According to the industry distribution chart, Alligator Bioscience AB ranks #989 out of 1404 companies in the Biotechnology industry, placing it in the top 70.4%.
Is Alligator Bioscience AB's EV-to-OCF too high?
Alligator Bioscience AB's current EV-to-OCF is -0.31. Based on the distribution chart, Alligator Bioscience AB ranks #989 out of 1404 companies in the Biotechnology industry, which is below the industry midpoint.
How does Alligator Bioscience AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #989 out of 1404 companies for EV-to-OCF. This places Alligator Bioscience AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Alligator Bioscience AB's current EV-to-OCF is -0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (OSTO:ATORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.02 — trading 140% above its estimated fair value. The current EV-to-OCF is -0.31. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Alligator Bioscience AB (OSTO:ATORX), the current EV-to-OCF is -0.31 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ATORX has been successfully added to your 
